

10. Rauscher I, Maurer T, Fendler WP, Sommer WH, Schwaiger M, Eiber M. ^{68}Ga -PSMA ligand PET/CT in patients with prostate cancer: how we review and report. *Cancer Imaging*. 2016;16:14.
11. Afshar-Oromieh A, Wolf M, Haberkorn U, et al. Effects of arm truncation on the appearance of the halo artifact in ^{68}Ga -PSMA-11 (HBED-CC) PET/MRI. *Eur J Nucl Med Mol Imaging*. 2017;44:1636–1646.
12. Heußler T, Mann P, Rank CM, et al. Investigation of the halo-artifact in ^{68}Ga -PSMA-11-PET/MRI. *PLoS One*. 2017;12:e0183329.
13. Watson CC, Newport D, Casey ME, Dekemp RA, Beanlands RS, Schmand M. Evaluation of simulation-based scatter correction for 3-D PET cardiac imaging. *IEEE Trans Nucl Sci*. 1997;44:90–97.
14. Watson CC. New, faster, image-based scatter correction for 3-D PET. *IEEE Trans Nucl Sci*. 2000;47:1587–1594.
15. Watson C, Hayden C, Casey M, Hamill J, Bendriem B. Prompt gamma correction for improved quantification in ^{82}Rb PET [abstract]. *J Nucl Med*. 2008;49:64P.
16. Hong I, Rothfuss H, Michel C, Casey M. Prompt gamma correction on Ga-68 PSMA PET studies. IEEE Xplore website. <https://ieeexplore.ieee.org/document/7582166>. Published October 6, 2016. Accessed June 11, 2019.
17. Watson CC, Hu J, Zhou C. Extension of the SSS PET scatter correction algorithm to include double scatter. IEEE Xplore website. <https://ieeexplore.ieee.org/document/4346746>. Published October 15, 2007. Accessed June 11, 2019.
18. Wangerin KA, Baratto L, Khalighi MM, et al. Clinical evaluation of ^{68}Ga -PSMA-II and ^{68}Ga -RM2 PET images reconstructed with an improved scatter correction algorithm. *AJR*. 2018;211:655–660.
19. Afshar-Oromieh A, Babich JW, Kratochwil C, et al. The rise of PSMA ligands for diagnosis and therapy of prostate cancer. *J Nucl Med*. 2016;57(suppl 3):79S–89S.
20. Eiber M, Weirich G, Holzpfel K, et al. Simultaneous ^{68}Ga -PSMA HBED-CC PET/MRI improves the localization of primary prostate cancer. *Eur Urol*. 2016;70:829–836.
21. Schwarzenboeck SM, Rauscher I, Bluemel C, et al. PSMA ligands for PET imaging of prostate cancer. *J Nucl Med*. 2017;58:1545–1552.
22. Lindemann ME, Oehmigen M, Blumhagen JO, Gratz M, Quick HH. MR-based truncation and attenuation correction in integrated PET/MR hybrid imaging using HUGE with continuous table motion. *Med Phys*. 2017;44:4559–4572.
23. Oehmigen M, Lindemann ME, Gratz M, et al. Impact of improved attenuation correction featuring a bone atlas and truncation correction on PET quantification in whole-body PET/MR. *Eur J Nucl Med Mol Imaging*. 2018;45:642–653.
24. Martinez-Möller A, Souvatzoglou M, Delso G, et al. Tissue classification as a potential approach for attenuation correction in whole-body PET/MRI: evaluation with PET/CT data. *J Nucl Med*. 2009;50:520–526.
25. Koesters T, Friedman KP, Fenchel M, et al. Dixon sequence with superimposed model-based bone compartment provides highly accurate PET/MR attenuation correction of the brain. *J Nucl Med*. 2016;57:918–924.
26. Paulus DH, Quick HH, Geppert C, et al. Whole-body PET/MR imaging: quantitative evaluation of a novel model-based MR attenuation correction method including bone. *J Nucl Med*. 2015;56:1061–1066.
27. Blumhagen JO, Ladebeck R, Fenchel M, Scheffler K. MR-based field-of-view extension in MR/PET: B0 homogenization using gradient enhancement (HUGE). *Magn Reson Med*. 2013;70:1047–1057.
28. Blumhagen JO, Braun H, Ladebeck R, et al. Field of view extension and truncation correction for MR-based human attenuation correction in simultaneous MR/PET imaging. *Med Phys*. 2014;41:022303.
29. Lückerkath K, Stuparu AD, Wei L, et al. Detection threshold and reproducibility of ^{68}Ga -PSMA11 PET/CT in a mouse model of prostate cancer. *J Nucl Med*. 2018;59:1392–1397.
30. Eiber M, Herrmann K, Calais J, et al. Prostate cancer molecular imaging standardized evaluation (PROMISE): proposed miTNM classification for the interpretation of PSMA-ligand PET/CT. *J Nucl Med*. 2018;59:469–478.
31. Rowe SP, Pienta KJ, Pomper MG, Gorin MA. Proposal for a structured reporting system for prostate-specific membrane antigen-targeted PET imaging: PSMA-RADS version 1.0. *J Nucl Med*. 2018;59:479–485.

Errata

In the article “Evaluation of ^{11}C -LSN3172176 as a Novel PET Tracer for Imaging M_1 Muscarinic Acetylcholine Receptors in Nonhuman Primates,” by Nabulsi et al. (*J Nucl Med*. 2019; 60:1147–1153), in Figure 2, $\text{C}(\text{O})\text{CH}_2\text{CH}_3$ and $^*\text{C}(\text{O})\text{CH}_2\text{CH}_3$ should be $\text{CO}_2\text{CH}_2\text{CH}_3$ and $^*\text{CO}_2\text{CH}_2\text{CH}_3$. The corrected figure appears below. The authors regret the error.




FIGURE 2. Novel selective agonist for M_1 mAChR. Boldface letter C with asterisk indicates ^{11}C -radiolabeling site.

In the article “Discussions with Leaders: A Conversation Between Nora Volkow and Johannes Czernin,” by Nora Volkow and Johannes Czernin (*J Nucl Med*. 2019; 60:717–720), the National Institute on Drug Abuse (NIDA) was incorrectly cited as “the National Institute of Drug Abuse” in two places. We regret the error.